Details for New Drug Application (NDA): 212791
✉ Email this page to a colleague
The generic ingredient in DEXMEDETOMIDINE HYDROCHLORIDE is dexmedetomidine hydrochloride. There are fourteen drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the dexmedetomidine hydrochloride profile page.
Summary for 212791
| Tradename: | DEXMEDETOMIDINE HYDROCHLORIDE |
| Applicant: | Wilshire Pharms Inc |
| Ingredient: | dexmedetomidine hydrochloride |
| Patents: | 0 |
Pharmacology for NDA: 212791
| Mechanism of Action | Adrenergic alpha2-Agonists |
| Physiological Effect | General Anesthesia |
Medical Subject Heading (MeSH) Categories for 212791
Suppliers and Packaging for NDA: 212791
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| DEXMEDETOMIDINE HYDROCHLORIDE | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 212791 | ANDA | Wilshire Pharmaceuticals, Inc. | 52536-125 | 52536-125-10 | 10 BOTTLE in 1 CARTON (52536-125-10) / 50 mL in 1 BOTTLE (52536-125-01) |
| DEXMEDETOMIDINE HYDROCHLORIDE | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 212791 | ANDA | Wilshire Pharmaceuticals, Inc. | 52536-126 | 52536-126-08 | 8 BOTTLE in 1 CARTON (52536-126-08) / 100 mL in 1 BOTTLE (52536-126-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) | ||||
| Approval Date: | Dec 4, 2019 | TE: | AP | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) | ||||
| Approval Date: | Dec 4, 2019 | TE: | AP | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML) | ||||
| Approval Date: | May 8, 2020 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
